Financial Performance - For the six months ended June 30, 2023, the company's revenue was RMB 15.28 billion, a slight increase of 0.5% compared to RMB 15.19 billion in the same period of 2022[2]. - The net profit for the same period was RMB 2.70 billion, representing a decrease of 15.2% from RMB 3.18 billion year-on-year[2]. - Profit attributable to equity holders of the parent company was RMB 1.26 billion, down 34.5% from RMB 1.92 billion in the previous year[2]. - Adjusted net profit not in accordance with Hong Kong Financial Reporting Standards was RMB 1.48 billion, an increase of 1.2% from RMB 1.46 billion in the same period last year[2][4]. - In Q2 2023, revenue was RMB 8.63 billion, a significant increase of 30.0% compared to RMB 6.64 billion in Q2 2022[2]. - The adjusted net profit for Q2 2023 was RMB 960 million, reflecting a growth of 20.7% from RMB 800 million in Q2 2022[2]. - The group recorded revenue of approximately RMB 1,527,704 million for the period, representing a year-on-year increase of about 0.5%[18]. - The group reported a profit attributable to equity holders of approximately RMB 125,878 million, a decrease of about 34.5% compared to the previous year[18]. - The net profit for the period was RMB 3,183,221 thousand, compared to RMB 3,545,258 thousand in the previous year, indicating a decrease of approximately 10.25%[54]. Revenue Breakdown - Innovative drug revenue reached RMB 3.86 billion, up 10.9% year-on-year, accounting for 25.3% of total revenue[2]. - Revenue from oncology drugs was approximately RMB 449,186 million, accounting for about 29.4% of total revenue, a decrease of approximately 9.4% year-on-year[19]. - Revenue from liver disease drugs was approximately RMB 228,931 million, accounting for about 15.0% of total revenue, an increase of approximately 14.0% year-on-year[19]. - Revenue from the modern Chinese medicine and Western medicine segment was RMB 14,963,976, contributing to total segment revenue of RMB 15,277,037[50]. Research and Development - The company continues to focus on innovation and aims to enhance its technology platform while expanding its international presence[7]. - The company launched two innovative products during the period and received approval for two biosimilars[11]. - The group has 127 products under development, including 60 oncology drugs, 10 liver disease drugs, 21 respiratory drugs, and 17 surgical/pain relief drugs, with 69 classified as innovative products[25]. - Research and development expenses for the six months ended June 30, 2023, amounted to approximately RMB 2,604.95 million, representing about 17.1% of the group's revenue[25]. - Research and development costs for the period were RMB 2,357,257 thousand, an increase from RMB 2,048,604 thousand in the previous year, indicating a focus on innovation[39]. Market and Regulatory Environment - The pharmaceutical manufacturing industry's revenue in China for the first half of 2023 was RMB 1,249.6 billion, a decrease of 2.9% year-on-year, while total profit fell by 17.1% to RMB 179.45 billion[11]. - The new rules issued by the National Medical Insurance Administration on July 21, 2023, clarified the management of drug inclusion in regular catalogs, benefiting the development of innovative drugs[11]. - The average price drop for the eighth batch of national drug centralized procurement was 56%, with 39 drugs successfully procured[11]. Corporate Governance and Recognition - The company has been recognized as one of the "Top 50 Pharmaceutical Companies" by Pharmaceutical Executive magazine for five consecutive years from 2019 to 2023[10]. - The company has been recognized as one of the 88 selected enterprises in the "Sustainable Development Yearbook (China Edition) 2023" by S&P Global, highlighting its commitment to ESG management[35]. - The group’s ESG index ranking was 57 out of 855 listed companies, receiving a rating of "leading level in ESG development" for its high-quality ESG management[35]. Capital and Financial Position - The group has cash and bank balances of approximately RMB 1,157,719 million, with total financial reserves amounting to approximately RMB 1,960,921 million[18]. - The total assets of the group were approximately RMB 65,640.89 million as of June 30, 2023, with total liabilities of approximately RMB 29,182.08 million, resulting in a debt ratio of approximately 44.5%[31]. - The group has implemented foreign exchange forward contracts to hedge part of its euro-denominated liabilities and will continue to monitor foreign exchange net risks[33]. - The group reported a net loss from its joint ventures and associates of approximately RMB 20,640 million after tax adjustments[22]. Shareholder Returns - The company declared an interim dividend of HKD 0.02 per share for the six months ended June 30, 2023[2]. - The interim dividend declared for the six months ended June 30, 2023, is HKD 0.02 per ordinary share, down from HKD 0.06 per share in 2022[66]. - The company repurchased a total of 12,650,000 shares at a total cost of approximately HKD 46,032,500 during the six months ended June 30, 2023[76]. Future Outlook - The company plans to launch nearly 10 innovative drugs in the next three years, with over 40 innovative drugs in the pipeline expected to be launched by 2030[36]. - The group aims to achieve a revenue target of HKD 100 billion by 2030, positioning itself as a world-class innovative pharmaceutical group[36].

Research and Development - The company reported a strong focus on research and development, with industry-leading investment in R&D and product innovation capabilities [8]. - Research and development expenses accounted for over 15% of total sales revenue, highlighting the company's commitment to innovation [28]. - The group reported a total R&D expenditure of approximately RMB 4,454.18 million, representing about 15.5% of the group's revenue, with over 74% of this investment allocated to innovative and biological drugs [64]. - The company has 40 innovative drug candidates in the oncology field at clinical application stages, with 8 expected to be approved for market in the next three years (2023-2025) [40]. - The company has 8 innovative drug candidates in the liver disease field, with 4 expected to be approved for market in the next three years (2023-2025) [41]. - The company has 10 innovative drug candidates in the respiratory system field at clinical application stage or above, including 1 in the market application stage and 5 in Phase II clinical trials [45]. - The company is conducting Phase II clinical trials for TDI01, a selective ROCK2 inhibitor, targeting conditions such as pneumoconiosis and COVID-19 [46]. - The company has submitted a market application for Enzastaurin, a new oral COVID-19 treatment, which shows significant improvement in symptoms associated with the Omicron variant [45]. - The company plans to launch several innovative drug products in the next three years, including TQB2450 and TQ-B3101, which are currently in the application stage [33]. Financial Performance - Revenue for 2022 reached RMB 28,780,412 thousand, an increase from RMB 26,861,356 thousand in 2021, representing a growth of approximately 7.1% [25]. - Gross profit for 2022 was RMB 22,984,902 thousand, compared to RMB 21,529,261 thousand in 2021, indicating a year-over-year increase of about 6.8% [25]. - The net profit for 2022 was RMB 5,002,618 thousand, a decrease from RMB 16,614,793 thousand in 2021, representing a decline of approximately 69.9% [25]. - The company reported a pre-tax profit of RMB 5,778,604 thousand for 2022, down from RMB 18,572,673 thousand in 2021, indicating a decline of approximately 68.9% [25]. - Profit attributable to equity holders decreased by approximately 82.6% to RMB 2,543.57 million, with earnings per share of RMB 0.1366, down about 82.4% [50]. - Adjusted net profit under non-HKFRS was approximately RMB 2,986.33 million, an increase of about 16.4% compared to the previous year [50]. - The company’s total liabilities increased to RMB 26,120,736 thousand in 2022 from RMB 22,814,314 thousand in 2021, marking an increase of about 14.0% [25]. - The total assets of the company increased to RMB 64,064,284 thousand in 2022, up from RMB 60,543,337 thousand in 2021, reflecting a growth of approximately 4.2% [25]. Market Position and Recognition - The company has been recognized as a leading innovative pharmaceutical group in China, with a comprehensive product portfolio covering oncology, liver disease, and respiratory diseases [8]. - The company was included in the MSCI Global Standard Index as a constituent stock of the China Index, effective May 31, 2013 [11]. - The company has been listed among the "Top 50 Global Pharmaceutical Companies" for four consecutive years from 2019 to 2022 [14]. - The company successfully bid for 9 products in the national procurement process, the highest number among listed pharmaceutical companies [38]. Corporate Governance and ESG Initiatives - The company has established an ESG vision focused on high-quality management to support the United Nations Sustainable Development Goals and the Healthy China strategy [73]. - The company received awards for being one of the "Best ESG Employers" in China in 2022, highlighting its commitment to ESG principles [73]. - The board of directors is focused on overall corporate strategy and financial performance, ensuring sustainable development aligned with the company's mission [76]. - The company has implemented a strategic planning process to identify and assess risks and opportunities, aiming to create long-term value for shareholders [78]. - The company has established an ESG committee under the board to oversee significant ESG-related matters and ensure the implementation of ESG strategies [71]. Employee and Management Structure - The group had approximately 26,272 employees as of December 31, 2022 [69]. - Employee costs, including director remuneration and equity-settled share-based payment expenses, totaled approximately RMB 4,750.93 million for the year, compared to RMB 4,568.98 million in the previous year, representing an increase of about 4.0% [69]. - The company emphasizes employee development through competitive compensation, performance assessments, and training opportunities [144]. - The leadership team has received multiple awards and recognitions for their contributions to the industry and society [170][172]. Strategic Initiatives and Future Outlook - The company aims to achieve a revenue target of HKD 100 billion by 2030, driven by the launch of over ten innovative drug products in the next three years and more than forty innovative drugs expected to be launched by 2030 [51]. - The company is actively pursuing market expansion and new strategies to enhance its competitive position in the pharmaceutical industry [35]. - The company is committed to developing new drugs and modern healthcare products for cardiovascular and respiratory diseases [164]. - The company is positioned for market expansion, leveraging the expertise of its board and management team [181].

Financial Performance - Revenue for the year ended December 31, 2022, was RMB 28.78 billion, an increase of 7.1% from RMB 26.86 billion in 2021[2] - Gross profit for the same period was RMB 22.98 billion, reflecting a growth of 6.8% compared to RMB 21.53 billion in the previous year[2] - Profit attributable to owners of the parent company significantly decreased by 82.6% to RMB 2.54 billion from RMB 14.61 billion in 2021[2] - Adjusted net profit attributable to owners of the parent company increased by 16.4% to RMB 2.99 billion from RMB 2.56 billion in the prior year[2] - The company recorded revenue of approximately RMB 2,878,041,000, representing a year-on-year growth of about 7.1%[17] - Net profit attributable to shareholders decreased by approximately 82.6% to RMB 254,357,000, with earnings per share dropping by about 82.4% to RMB 0.1366[17] - Adjusted net profit, after accounting for various financial adjustments, increased by approximately 16.4% to RMB 298,633,000[17] - The company's annual profit for the year ended December 31, 2022, was RMB 5,002,618, a significant decrease from RMB 16,614,793 in 2021, representing a decline of approximately 69.9%[42] - Total comprehensive income for the year, after tax, was RMB 4,289,080, down from RMB 16,815,754 in the previous year, indicating a decrease of about 74.5%[43] Revenue Breakdown - Revenue from new products reached RMB 12.51 billion, representing a 19.8% increase from RMB 10.45 billion in 2021, accounting for 43.5% of total revenue[2] - Revenue from anti-tumor drugs was RMB 9.19 billion, up 14.3% from RMB 8.04 billion, making up 31.9% of total revenue[2] - Revenue from innovative drugs increased by 20.0% to RMB 6.75 billion from RMB 5.63 billion, representing 23.5% of total revenue[2] - Surgical and analgesic drug revenue for the year ended December 31, 2022, was approximately RMB 4,881.77 million, accounting for 17% of total revenue, an increase of about 2.8% year-over-year[20] - Cardiovascular drug revenue for the year ended December 31, 2022, was approximately RMB 2,697.50 million, representing about 9.4% of total revenue, with a year-over-year growth of approximately 7.8%[20] - Other revenue for the year ended December 31, 2022, was approximately RMB 5,249.14 million, accounting for about 18.2% of total revenue, an increase of approximately 2.5% year-over-year[21] Research and Development - The company emphasizes R&D and innovation, maintaining industry-leading R&D investment and product innovation capabilities[4] - Research and development (R&D) expenses totaled approximately RMB 4,454.18 million, accounting for about 15.5% of the group's revenue, with a year-on-year increase of approximately 19% in innovative and biological drug R&D investment[27] - The group has 103 products under development, including 53 oncology drugs, 12 liver disease drugs, 26 respiratory drugs, and 12 surgical/pain relief drugs, with 58 being innovative products[27] - The company has 40 innovative drug candidates in the oncology field at various clinical stages, with 8 innovative drugs expected to be approved between 2023 and 2025[10] - The company has 8 innovative drug candidates in the liver disease field, with 4 biosimilars or generics expected to be approved between 2023 and 2025[12] - The company has 10 innovative drug candidates in the respiratory system field at clinical application stage or above, including 1 in the market application stage and 5 in Phase II clinical trials[14] Market and Industry Context - In 2022, China's GDP reached RMB 121 trillion, growing by 3% year-on-year[8] - The revenue of China's pharmaceutical manufacturing industry decreased by 1.6% year-on-year to RMB 291.114 billion in 2022[8] - The total profit of the pharmaceutical manufacturing industry fell by 31.8% year-on-year to RMB 42.887 billion in 2022[8] - The average price drop for 327 selected products in the seventh batch of national drug procurement was 48%[9] - China National Pharmaceutical Group won bids for 9 out of 11 products in the procurement, primarily for newly launched products[9] Corporate Governance and Shareholder Engagement - The company actively engages with investors through various channels, including investor briefings and participation in investment summits, to enhance corporate governance and transparency[28] - The company has implemented a share repurchase plan with a budget of up to HKD 1 billion, of which HKD 916.64 million has been utilized for share repurchases and incentive share purchases[34] - The audit committee consists of four independent non-executive directors, ensuring compliance with listing rules regarding financial management expertise[72] - The company has adhered to the Corporate Governance Code, with minor deviations noted regarding attendance at the annual general meeting[71] - The company is committed to maintaining adequate independent director representation as per listing regulations[72] Financial Position and Assets - The total assets of the group were approximately RMB 64,064.28 million, with total liabilities of approximately RMB 26,120.74 million, resulting in a debt-to-asset ratio of approximately 40.8%[32] - As of December 31, 2022, the group's cash and bank balances were approximately RMB 12,066.22 million, an increase from RMB 10,568.81 million as of December 31, 2021[29] - The company held non-current equity investments valued at approximately RMB 1,574.81 million as of December 31, 2022, down from RMB 1,988.24 million the previous year[25] - The total amount of wealth management products held by the company was approximately RMB 4,543.24 million, accounting for about 7.1% of total assets as of December 31, 2022[26] - The company's net assets stood at RMB 37,943,548 as of December 31, 2022, slightly up from RMB 37,729,023 in 2021, indicating a growth of about 0.6%[45] Future Outlook - The company plans to launch over ten innovative drug products in the next three years, with more than forty innovative drugs expected to be launched by 2030[39] - The company aims to achieve a revenue target of HKD 100 billion by 2030, positioning itself as a world-class innovative pharmaceutical group[39] - The company has completed carbon inventory work for key member enterprises as part of its carbon neutrality planning project, with a roadmap expected to be published by mid-2023[37] - The company continues to focus on four strategic areas: organizational integration, comprehensive innovation, internationalization, and digitalization to enhance operational efficiency[39]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 15.19 billion, an increase of 5.9% from RMB 14.35 billion in 2021[9] - Gross profit for the same period was RMB 12.23 billion, reflecting a 5.5% increase from RMB 11.60 billion in the previous year[9] - Profit attributable to owners of the parent decreased by 77.3% to RMB 1.92 billion from RMB 8.48 billion in 2021[9] - Adjusted net profit attributable to owners of the parent was RMB 1.66 billion, up 4.5% from RMB 1.59 billion in the prior year[9] - Total comprehensive income for the period was RMB 2,575,491, significantly lower than RMB 9,905,092 in the prior year[51] - The company reported a net profit of RMB 3,183,221 for the six months ended June 30, 2022, compared to RMB 9,641,604 for the same period in 2021, indicating a significant decrease[63] - The profit from equity investments at fair value through profit or loss was RMB 154,199,000 for the first half of 2022, compared to a loss of RMB 19,618,000 in the same period of 2021, indicating a significant turnaround[72] - The profit attributable to equity holders of the parent company for the six months ended June 30, 2022, was RMB 1,921,037,000, a decrease of 77.3% compared to RMB 8,480,340,000 for the same period in 2021[78] Revenue Breakdown - Revenue from new products reached RMB 6.61 billion, representing a 24.6% increase and accounting for 43.5% of total revenue[9] - Revenue from anti-tumor drugs was RMB 4.96 billion, a 16.7% increase, making up 32.6% of total revenue[9] - Revenue from innovative drugs was RMB 3.49 billion, up 14.2%, contributing 22.9% to total revenue[9] - Sales revenue from new products increased from approximately 36.9% to 43.5% of total revenue[25] - Revenue from surgical/pain relief drugs was approximately RMB 252,050 million, accounting for about 16.6% of total revenue, with a growth of about 7.1% year-on-year[26] - Revenue from liver disease drugs was approximately RMB 200,891 million, accounting for about 13.2% of total revenue, with a growth of about 11.1% year-on-year[27] - Revenue from cardiovascular drugs was approximately RMB 155,220 million, accounting for about 10.2% of total revenue, with a growth of about 13.8% year-on-year[29] Research and Development - The company emphasizes R&D and innovation, maintaining industry-leading investment in R&D and product innovation capabilities[12] - The group has a total of 418 products under research and development, including 230 oncology drugs and 29 liver disease drugs, as of June 30, 2022[35] - Research and development expenses for the six months ended June 30, 2022, totaled approximately RMB 2,191.59 million, representing 14.4% of the group's revenue, compared to 13.1% in the previous year[35] - Research and development costs for the period were RMB 2,048,604, compared to RMB 1,781,597 in the same period last year, indicating a focus on innovation[50] - The company is focusing on high-innovation and high-market-potential products in its pipeline, reassessing its R&D investments in light of the potential impacts of national procurement policies on generic drugs[47] Market and Economic Context - In the first half of 2022, China's GDP reached RMB 56.3 trillion, with a year-on-year growth of 2.5%[18] - The pharmaceutical manufacturing industry's revenue growth in Q1 2022 was lower than GDP growth, primarily due to the high base from the previous year and ongoing pandemic impacts[18] - In Q2 2022, the severe pandemic affected medical service volumes and pharmaceutical consumption, leading to a decline in healthcare expenditure and consumer income levels[18] Corporate Governance and ESG - The company has committed to a comprehensive ESG governance strategy, focusing on disease treatment, pharmaceutical accessibility, environmental friendliness, and win-win relationships[44] - The company has initiated the construction of an ESG digital platform, expected to be fully operational by Q4 2022, to improve ESG management through data visualization and performance tracking[45] - The company has not experienced any significant ESG-related risk incidents in the first half of 2022, indicating effective risk management practices[45] - The company held six monthly ESG management committee meetings in the first half of 2022, ensuring over 75% attendance from committee members[45] Shareholder Information - As of June 30, 2022, the company had a total issued share capital of 18,800,000,000 shares[100] - Ms. Xie Qirun holds 2,279,254,761 shares, representing approximately 12.11% of the total issued share capital[101] - Mr. Xie Chengrun holds 4,050,000,000 shares, accounting for 21.53% of the total issued share capital[101] - The company has a stock option plan approved on May 28, 2013, allowing for the issuance of shares not exceeding 10% of the total issued share capital at the time of adoption[107] - The company’s stock option grants to major shareholders require prior approval from independent non-executive directors[107] Cash Flow and Liquidity - The net cash flow from operating activities for the six months ended June 30, 2022, was RMB 3,948,941, compared to RMB 2,335,554 for the same period in 2021, representing a significant increase[57] - Cash and bank balances decreased to RMB 7,768,292 from RMB 10,568,812 at the end of 2021, reflecting liquidity challenges[52] - The company experienced a net decrease in cash and cash equivalents of RMB (3,501,245) for the first half of 2022, compared to RMB (2,482,102) in the same period of 2021[57] Investment and Capital Expenditure - The company issued €750 million zero-coupon convertible bonds due in 2025, with net proceeds allocated for R&D, production facilities, sales, and general corporate purposes[111] - The group had capital commitments of RMB 1,717,675,000 as of June 30, 2022, compared to RMB 910,967,000 as of December 31, 2021, reflecting an increase of 88.8%[84] - Capital expenditure for the six months ended June 30, 2022, was RMB 789,555, compared to RMB 566,721 in the same period of 2021, showing an increase of approximately 39.3%[63]

Financial Performance - Revenue for 2021 was RMB 26.9 billion, with a net profit of RMB 16.6 billion[15]. - The company's revenue for the year 2021 reached RMB 26,861,356 thousand, an increase from RMB 23,647,224 thousand in 2020, representing a growth of approximately 9.4%[31]. - Gross profit for 2021 was RMB 21,529,261 thousand, compared to RMB 18,464,904 thousand in 2020, indicating a growth of about 16.4%[31]. - The operating profit for 2021 was RMB 5,112,091 thousand, showing an increase from RMB 4,527,582 thousand in 2020, which is a growth of approximately 12.9%[32]. - The net profit attributable to equity holders of the parent company for 2021 was RMB 14,608,412 thousand, significantly higher than RMB 2,771,086 thousand in 2020, marking an increase of approximately 426.5%[31]. - The net profit attributable to equity holders for the year was RMB 16,614,793,000, significantly up from RMB 4,340,667,000 in 2020, reflecting a year-over-year increase of approximately 284%[113]. - The company reported a significant increase in other income and profits, totaling RMB 1,068,929 thousand in 2021, compared to RMB 1,241,223 thousand in 2020[31]. - The company achieved a total revenue of approximately RMB 26.86 billion in the fiscal year, representing a year-on-year growth of about 13.6%[50]. - The basic earnings per share for the year ended December 31, 2021, was RMB 15.62, an increase from RMB 12.31 in the previous year[59]. Research and Development - The company has a strong focus on R&D, with industry-leading investment and innovation capabilities[6]. - Research and development expenses accounted for over 14% of total sales revenue, highlighting the company's commitment to innovation[33]. - The company is investing heavily in R&D, with a projected budget increase of 15% for the upcoming fiscal year[37]. - The total R&D expenditure for the year was approximately RMB 3,820.17 million, representing about 14.2% of the group's revenue, with a year-on-year increase of approximately 64.7% in investment for innovative drugs and biopharmaceuticals[65]. - The company obtained 36 new product approvals and submitted 52 clinical applications, including 26 for innovative drugs in 2021[49]. - The company plans to enhance its R&D innovation strategy and focus on unmet clinical needs in oncology, liver disease, and cardiovascular areas[51]. Market Expansion and Strategy - The company is actively expanding its market presence and leveraging big data and artificial intelligence to enhance operational efficiency[6]. - The company aims to expand its market presence significantly, focusing on both domestic and international markets[39]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[28]. - The company has identified strategic acquisition opportunities to enhance its product portfolio and market reach[39]. - The company plans to launch 20 new products in the respiratory system and musculoskeletal fields over the next three years, including HBQ and LM[37]. - The revenue from the respiratory system segment reached RMB 22.42 billion in 2021, showing a substantial growth compared to previous years[34]. Corporate Governance - The company has established various committees, including the Audit Committee, Remuneration Committee, and Nomination Committee, to oversee governance and compliance[86]. - The board consists of nine executive directors, including the chairperson and CEO, and five independent directors[79]. - Independent directors account for more than one-third of the board, providing valuable independent perspectives and advice[80]. - The board meets at least four times a year, with additional special meetings as necessary[78]. - The chairperson and CEO roles are separated, with the chairperson overseeing board operations and the CEO managing the group's business[82]. - The board is responsible for reviewing and monitoring compliance with legal and regulatory requirements[81]. Social Responsibility and Community Engagement - The company donated RMB 5 million and emergency relief materials worth RMB 5 million to support disaster relief efforts in Henan Province[48]. - The group actively engages in community investment and corporate social responsibility initiatives, including pandemic response and educational donations[73]. - The company is committed to providing a healthy and safe working environment for employees through various activities, including health checks and safety management[121]. - The company has implemented environmental protection measures, including energy conservation and waste reduction, to enhance its environmental performance[120]. Financial Position and Assets - The total assets of the company as of 2021 were RMB 60,543,337 thousand, up from RMB 47,210,438 thousand in 2020, reflecting a growth of about 28.5%[31]. - The total liabilities decreased to RMB 22,814,314 thousand in 2021 from RMB 24,790,880 thousand in 2020, indicating a reduction of about 7.9%[31]. - The company reported a net asset value of RMB 40 billion in 2021, with cash and bank balances amounting to RMB 37.73 billion[34]. - The company’s total reserves increased to RMB 30,565,023,000 by the end of 2021, up from RMB 16,801,209,000 at the end of 2020, reflecting a growth of approximately 82%[173]. Shareholder Information - The company proposed a final dividend of HKD 0.04 per share for the year ended December 31, 2021, subject to shareholder approval[110]. - The company maintains a consistent policy of providing stable and sustainable dividends, dependent on financial performance and cash flow[108]. - The top five customers accounted for less than 30% of total sales, indicating a diversified customer base[119]. Compliance and Risk Management - The company adheres to relevant Chinese laws and regulations regarding drug research and development, production, and distribution, ensuring compliance without significant violations[122]. - The group has established a risk compliance committee to enforce risk management protocols and ensure comprehensive risk assessment and control[73]. - The company is closely monitoring foreign exchange net risks to mitigate the impact of currency fluctuations on its assets and liabilities[72]. Leadership and Management - The company has a strong leadership team with extensive experience in management and investment in the pharmaceutical sector[143]. - The Chief Financial Officer, Ms. Ma Jiayin, holds an MBA from Columbia Business School and has over 20 years of financial management experience[151]. - The company appointed Professor Mao Li as Chief Medical Officer, bringing 35 years of oncology clinical practice and research experience[151]. - The company has a diverse board with members who have significant academic and professional backgrounds in finance, management, and pharmaceuticals, enhancing its strategic decision-making capabilities[148].

Corporate Information [Directors and Committees](index=2&type=section&id=Directors%20and%20Committees) The report lists the company's executive directors, independent non-executive directors, and members of key committees - The Board of Directors comprises nine executive and five independent non-executive directors, with four core committees established: Audit, Remuneration, Nomination, and ESG[7](index=7&type=chunk) [Key Business Partners](index=3&type=section&id=Key%20Business%20Partners) The report discloses key partners including principal bankers, share registrars, legal advisors, and the auditor - The company's principal bankers include The Hongkong and Shanghai Banking Corporation Limited, Bank of China (Hong Kong) Limited, and Agricultural Bank of China, Lianyungang Branch[9](index=9&type=chunk) - The company's auditor is Ernst & Young[13](index=13&type=chunk) Financial and Business Summary [Financial Highlights](index=4&type=section&id=Financial%20Highlights) The company achieved strong growth in H1 2021, driven by a 13.5% revenue increase and a 583.6% surge in net profit Financial Highlights for H1 2021 (as of June 30) | Indicator | H1 2021 (RMB in thousands) | H1 2020 (RMB in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 14,353,781 | 12,647,775 | +13.5% | | Gross Profit | 11,600,660 | 9,855,731 | +17.7% | | Profit for the Period | 9,641,604 | 2,064,127 | +367.1% | | Profit attributable to owners of the parent | 8,480,340 | 1,240,612 | +583.6% | | Adjusted profit attributable to owners* | 1,574,765 | 1,281,800 | +22.9% | | New Product Sales | 6,300,563 | 4,405,867 | +43.0% | | Oncology Drug Sales | 5,025,351 | 4,017,557 | +25.1% | - The Board declared a quarterly dividend of **2 HK cents per share** for the three months ended June 30, 2021, bringing the total H1 dividend to 4 HK cents per share[16](index=16&type=chunk) [Company Profile and Main Products](index=5&type=section&id=Company%20Profile%20and%20Main%20Products) The company is a leading innovative R&D-driven pharmaceutical group with a fully integrated business chain - The company is positioned as an R&D-driven pharmaceutical group with a fully integrated value chain covering R&D, intelligent manufacturing, and a strong sales system[19](index=19&type=chunk) Main Products by Therapeutic Area | Therapeutic Area | Key Product Examples | | :--- | :--- | | Oncology | Qingkeshu (Abiraterone Acetate), Qianping (Bortezomib for Injection), Anxian (Lenalidomide) | | Liver Disease | Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection), Tianqing Ganping (Dianmonium Glycyrrhizinate Enteric-coated Capsules) | | Cardiovascular | Yilunping (Irbesartan/Hydrochlorothiazide), Kaina (Beraprost Sodium) | | Orthopedics | Gaisanchun (Calcitriol), Yigu (Zoledronic Acid) | | Respiratory | Tianqingsuchang (Budesonide Suspension for Inhalation) | [Company Milestones](index=6&type=section&id=Company%20Milestones) The company has achieved leading positions in drug consistency evaluations and has been included in major stock indices - The company's subsidiary, CTTQ, was the first in China to pass the generic drug consistency evaluation and launched its Class 1 innovative anti-tumor drug Focus V (Anlotinib) in 2018[22](index=22&type=chunk)[24](index=24&type=chunk) - The company was included as a constituent stock of the **Hang Seng Index in September 2018** and the **Hang Seng China Enterprises Index in December 2019**[24](index=24&type=chunk) Management Discussion and Analysis [Industry Review](index=8&type=section&id=Industry%20Review) The normalization of volume-based procurement and healthcare reforms created new opportunities for leading pharmaceutical firms - The normalization of national volume-based procurement allows high-quality new products to achieve rapid market penetration and sales volume with lower promotion costs, benefiting R&D-focused companies[26](index=26&type=chunk) - Inter-provincial settlement of medical insurance and "dual-channel" policies have improved drug accessibility through both medical institutions and pharmacies[26](index=26&type=chunk) - "Internet + Healthcare" policies have made online drug sales and promotion a key supplement to traditional channels[26](index=26&type=chunk) [Business Review](index=9&type=section&id=Business%20Review) The company delivered strong business performance with significant contributions from new products and a continuously optimized R&D pipeline [Core Products and Marketing Performance](index=9&type=section&id=Core%20Products%20and%20Marketing%20Performance) Core products like Anlotinib maintained rapid growth while new marketing channels were successfully expanded - Over 60 new products launched since 2018 contributed **over 80% of sales growth** and now account for **over 40% of sales revenue**[29](index=29&type=chunk) - The core oncology drug Focus V (Anlotinib Hydrochloride Capsules) maintained rapid growth, while the first-to-market generic respiratory drug Tianqingsuchang (Budesonide Suspension for Inhalation) became a new growth driver[29](index=29&type=chunk) - The company actively expanded into new channels like chain pharmacies and primary care hospitals, achieving strong results for multiple product lines[30](index=30&type=chunk) - The company had **11 products selected** in the fifth round of national volume-based procurement, expecting rapid volume growth[28](index=28&type=chunk) [R&D Progress](index=9&type=section&id=R&D%20Progress) The company's R&D pipeline yielded significant results, with numerous approvals and a patent portfolio exceeding 1,000 R&D Achievements in H1 2021 | Item | Q2 | H1 Cumulative | | :--- | :--- | :--- | | Marketing Authorizations | 10 | 17 | | Clinical Trial Approvals | 17 | 24 | | Consistency Evaluation Approvals | 22 | 34 | | New Drug Applications Submitted | 8 | 12 | | Invention Patents Granted | 55 | 94 | - As of the period end, New Drug Applications had been submitted for four major biologics, including Penpulimab and Adalimumab[28](index=28&type=chunk) - The cumulative number of granted invention patents reached **1,018** by the end of the period[28](index=28&type=chunk) [Financial Performance Analysis](index=12&type=section&id=Financial%20Performance%20Analysis) The company's financial performance was outstanding, with net profit soaring 583.6% due to significant contributions from associate Sinovac [Overall Financial Performance](index=12&type=section&id=Overall%20Financial%20Performance) The company recorded revenue of RMB 14.35 billion and net profit attributable to the parent of RMB 8.48 billion Core Financial Data for H1 2021 | Indicator | Amount (RMB) | Y-o-Y Growth | | :--- | :--- | :--- | | Revenue | 14.35 billion | +13.5% | | Net Profit Attributable to Parent | 8.48 billion | +583.6% | | Earnings Per Share | 45.15 cents | +584.1% | | Adjusted Net Profit Attributable to Parent | 1.57 billion | +22.9% | - Sales revenue from new products increased its share of total revenue to **43.9%** from 34.8% in the prior year period[34](index=34&type=chunk) [Revenue by Therapeutic Area](index=12&type=section&id=Revenue%20by%20Therapeutic%20Area) Oncology drugs were the largest revenue source, accounting for 35.0% of total revenue in a diversified portfolio Sales and Revenue Share by Therapeutic Area for H1 2021 | Therapeutic Area | Sales (RMB in millions) | Share of Total Revenue (%) | | :--- | :--- | :--- | | Oncology | 5,025.4 | 35.0% | | Liver Disease | 1,991.9 | 13.9% | | Cardiovascular | 1,495.4 | 10.4% | | Orthopedics | 1,245.4 | 8.7% | | Respiratory | 1,062.9 | 7.4% | | Parenteral Nutrition | 594.6 | 4.1% | | Others | 2,938.1 | 20.5% | [Investments in Associates and Joint Ventures](index=13&type=section&id=Investments%20in%20Associates%20and%20Joint%20Ventures) Associates and joint ventures, particularly Sinovac, contributed significantly to the Group's profit during the period - Associates and joint ventures contributed a total profit of approximately RMB 7.58 billion, resulting in a net after-tax contribution of approximately **RMB 6.91 billion**[40](index=40&type=chunk) - The investment in **Sinovac** was a primary profit driver, with its COVID-19 vaccine CoronaVac approved in over 50 countries and an annual production capacity exceeding 2 billion doses[40](index=40&type=chunk) [Financial Asset Investments](index=14&type=section&id=Financial%20Asset%20Investments) The Group held a diversified portfolio of equity investments and financial assets to generate favorable returns - As of the period end, the Group held non-current equity investments at FVTOCI of approximately RMB 2.14 billion and current equity investments at FVTPL of approximately RMB 0.42 billion[41](index=41&type=chunk) - The Group invested approximately **RMB 9.41 billion** in wealth management products, accounting for about 16.7% of total assets[41](index=41&type=chunk) [R&D, Liquidity and Capital Structure](index=15&type=section&id=R&D,%20Liquidity%20and%20Capital%20Structure) The company maintained strong R&D investment, robust liquidity, and a healthy capital structure [R&D Investment and Intellectual Property](index=15&type=section&id=R&D%20Investment%20and%20Intellectual%20Property) The company invested heavily in R&D, with total expenditure reaching RMB 1.88 billion, or 13.1% of revenue - For the six months ended June 30, 2021, total R&D expenditure was approximately **RMB 1.88 billion**, representing about 13.1% of the Group's revenue[43](index=43&type=chunk) - The R&D pipeline included **393 products**, with a focus on oncology (185), liver disease (39), and respiratory (25)[43](index=43&type=chunk) - During H1, the company filed 161 new patent applications and accumulated a total of **1,018 granted invention patents**[43](index=43&type=chunk) [Liquidity and Capital Structure](index=15&type=section&id=Liquidity%20and%20Capital%20Structure) The Group maintained a healthy capital structure with RMB 8.03 billion in cash and bank balances as of June 30, 2021 Capital Structure Overview (June 30, 2021) | Item | Amount (RMB in millions) | | :--- | :--- | | Cash and bank balances | 8,028.3 | | Short-term loans | 1,824.7 | | Long-term loans | 6,273.3 | | Convertible bonds (debt component) | 5,242.6 | [Operations and Risk Management](index=16&type=section&id=Operations%20and%20Risk%20Management) The Group employed over 24,000 people, maintained a healthy gearing ratio, and actively managed foreign exchange risk - As of June 30, 2021, the Group's total assets were approximately RMB 56.21 billion and total liabilities were RMB 25.10 billion, with a **gearing ratio of 44.7%**, down from 52.5% at the end of 2020[47](index=47&type=chunk) [Employees and Remuneration Policy](index=16&type=section&id=Employees%20and%20Remuneration%20Policy) The Group had 24,443 employees and maintained share option and award schemes to incentivize key talent - As of June 30, 2021, the Group had **24,443 employees**, with total staff costs for the period amounting to approximately RMB 2.31 billion[48](index=48&type=chunk) - The company has a 2013 Share Option Scheme and a 2018 Share Award Scheme, though no options or shares were granted during the period[48](index=48&type=chunk) [Foreign Exchange Risk](index=17&type=section&id=Foreign%20Exchange%20Risk) The Group closely monitors its net exposure to foreign exchange risk to mitigate the impact of currency fluctuations - Most of the Group's assets and liabilities are denominated in RMB, USD, EUR, and HKD, and the Group closely monitors its foreign exchange risk[50](index=50&type=chunk) [Outlook](index=17&type=section&id=Outlook) The Group will focus on developing new marketing channels and prioritizing high-potential innovative products in its R&D pipeline - In the future, more resources will be allocated to new marketing channels and methods to gradually increase their revenue contribution[50](index=50&type=chunk) - The R&D pipeline has been optimized to focus on products with high innovation and market potential, increasing the future proportion of innovative drugs and high-barrier biologics[50](index=50&type=chunk) Condensed Consolidated Financial Statements [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=18&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2021, the Group reported revenue of RMB 14.35 billion and a net profit of RMB 8.48 billion Consolidated Income Statement Summary (For the six months ended June 30, 2021) | Item (RMB in thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Revenue | 14,353,781 | 12,647,775 | | Gross Profit | 11,600,660 | 9,855,731 | | Share of profits and losses of associates and joint ventures | 7,584,980 | (41,188) | | Profit before tax | 10,978,515 | 2,610,452 | | Profit for the period | 9,641,604 | 2,064,127 | | Profit attributable to owners of the parent | 8,480,340 | 1,240,612 | [Consolidated Statement of Financial Position](index=20&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2021, the Group's total assets were RMB 56.21 billion and net assets were RMB 31.11 billion Consolidated Statement of Financial Position Summary | Item (RMB in thousands) | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | Total Assets | 56,206,729 | 47,210,438 | | Total Liabilities | 25,097,657 | 24,790,880 | | Net Assets | 31,109,072 | 22,419,558 | | Equity attributable to owners of the parent | 24,575,623 | 16,747,160 | | Cash and bank balances | 8,028,326 | 11,259,084 | [Consolidated Statement of Changes in Equity](index=22&type=section&id=Consolidated%20Statement%20of%20Changes%20in%20Equity) Equity attributable to owners of the parent increased from RMB 16.75 billion to RMB 24.58 billion, driven by net profit - Equity attributable to owners of the parent increased from **RMB 16.75 billion** at year-end 2020 to **RMB 24.58 billion** as of June 30, 2021, primarily driven by profit for the period[59](index=59&type=chunk) [Condensed Consolidated Statement of Cash Flows](index=23&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) The Group generated net cash from operating activities of RMB 2.34 billion, while cash and cash equivalents decreased by RMB 2.48 billion Condensed Consolidated Statement of Cash Flows Summary (For the six months ended June 30) | Item (RMB in thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Cash flows from operating activities | 2,335,554 | 1,555,549 | | Cash flows from investing activities | (4,055,967) | (1,533,585) | | Cash flows from financing activities | (761,689) | 5,110,430 | | Net decrease in cash and cash equivalents | (2,482,102) | 5,132,394 | | Cash and cash equivalents at end of period | 8,028,326 | 15,666,602 | Notes to the Financial Statements [Basis of Preparation and Operating Segments](index=24&type=section&id=Basis%20of%20Preparation%20and%20Operating%20Segments) The Group's business is divided into three reportable segments, with Western and biological pharmaceuticals being the primary source of revenue Segment Results for H1 2021 | Segment (RMB in thousands) | External Revenue | Segment Results | | :--- | :--- | :--- | | Western and biological pharmaceuticals | 14,062,845 | 3,615,278 | | Investment | 1,362 | (7,764) | | Others | 289,574 | (9,933) | | **Total** | **14,353,781** | **3,597,581** | - Over **90% of the Group's revenue** is derived from customers in Mainland China[71](index=71&type=chunk) [Revenue and Profit Analysis](index=30&type=section&id=Revenue%20and%20Profit%20Analysis) The Group's profit before tax was calculated after deducting R&D expenses of RMB 1.78 billion - During the reporting period, R&D expenses were **RMB 1.78 billion** and total staff costs were **RMB 2.31 billion**[77](index=77&type=chunk) - Key subsidiaries of the Group, such as CTTQ and Beijing Tide, are recognized as "High and New Technology Enterprises" and benefit from a preferential corporate income tax rate of **15%**[79](index=79&type=chunk) [Dividends and Earnings Per Share](index=33&type=section&id=Dividends%20and%20Earnings%20Per%20Share) The Board declared a Q2 2021 dividend of 2 HK cents per share, with basic EPS for the period at RMB 45.15 cents - The Board of Directors declared a quarterly dividend of **2 HK cents per share** for the three months ended June 30, 2021[82](index=82&type=chunk) Earnings Per Share Calculation | Item | H1 2021 | H1 2020 | | :--- | :--- | :--- | | Basic Earnings Per Share | RMB 45.15 cents | RMB 6.60 cents | | Diluted Earnings Per Share | RMB 43.38 cents | RMB 6.60 cents | [Key Asset and Liability Items](index=35&type=section&id=Key%20Asset%20and%20Liability%20Items) Trade and bills receivables totaled RMB 5.06 billion with a healthy aging profile, while trade and bills payables were RMB 1.62 billion - As of June 30, 2021, trade and bills receivables amounted to approximately **RMB 5.06 billion**, with about RMB 4.70 billion (approx. 93%) aged within 90 days[88](index=88&type=chunk)[89](index=89&type=chunk) - As of June 30, 2021, trade and bills payables amounted to approximately **RMB 1.62 billion**[91](index=91&type=chunk) Other Information [Directors' and Chief Executive's Interests in Shares](index=38&type=section&id=Directors'%20and%20Chief%20Executive's%20Interests%20in%20Shares) The Tse family holds a significant combined stake in the company, reflecting strong family control - Mr Tse, Shing Yuk is the largest shareholder, holding a total interest of approximately **21.47%** in the company's shares[97](index=97&type=chunk) - Ms Tse, Theresa Y Y (Chairwoman) holds approximately **12.08%** of the shares, and Mr Tse Ping (Senior Vice Chairman) holds approximately **8.40%**[97](index=97&type=chunk) [Share Incentive Schemes](index=41&type=section&id=Share%20Incentive%20Schemes) The company has two share incentive schemes in place, but no options or shares were granted during the period - The company has a 2013 Share Option Scheme with a ten-year validity, but no options have been granted since its adoption[106](index=106&type=chunk)[108](index=108&type=chunk) - The company adopted a Share Award Scheme in 2018, allowing the trustee to purchase up to 3% of issued share capital for awards, but no shares have been granted since adoption[109](index=109&type=chunk) [Investor Relations and Corporate Governance](index=43&type=section&id=Investor%20Relations%20and%20Corporate%20Governance) The Group is committed to high standards of corporate governance and actively engages with the investment community - The Group actively conducts investor relations activities and was honored as a "Most Honored Company" in the Institutional Investor "2021 All-Asia Executive Team" rankings[111](index=111&type=chunk) - The company complied with most provisions of the Corporate Governance Code but noted the absence of the Chairwoman and three independent directors from the Annual General Meeting[114](index=114&type=chunk) - The company established a new **Environment, Social and Governance (ESG) Committee** on August 31, 2021, to enhance its focus in this area[122](index=122&type=chunk)

Financial Performance - Revenue for 2020 was RMB 23.6 billion, with a net profit of RMB 4.3 billion[36] - The company's revenue for 2020 was RMB 23,647,224 thousand, with a gross profit of RMB 18,464,904 thousand, reflecting a gross margin of approximately 78%[40] - The net profit for 2020 was RMB 4,340,667 thousand, a decrease from RMB 4,787,845 thousand in 2019[40] - The total revenue for 2020 was approximately RMB 23,647.22 million, a slight decrease of about 2.4% compared to the previous year[70] - Profit attributable to equity holders of the parent company was approximately RMB 2,771.09 million, a slight increase of about 0.3% year-on-year[70] - Gross profit for 2020 was RMB 18,464,904, compared to RMB 19,307,762 in 2019, reflecting a decline of 4.4%[143] - Total assets increased to RMB 47,134,653 in 2020, up from RMB 37,514,192 in 2019, representing a growth of 25.0%[143] - Total liabilities rose to RMB 24,788,069 in 2020, compared to RMB 16,953,010 in 2019, marking an increase of 46.5%[143] Research and Development - The company emphasizes R&D and innovation, with industry-leading R&D investment and product innovation capabilities[30] - Research and development expenses accounted for over 12% of total sales revenue, indicating a strong commitment to innovation[43] - The company’s R&D spending has been consistently increasing, reflecting its strategy to enhance product offerings and market competitiveness[43] - Total R&D expenditure for the year ended December 31, 2020, was approximately RMB 2,852.68 million, accounting for about 12.1% of the company's revenue[86] - The company has a strong product pipeline with 191 patent grants, including 158 invention patents, maintaining a leading position among domestic pharmaceutical companies[69] Product Development and Launches - The company plans to launch 20 new products in 2021, including several oncology and orthopedic drugs that have already received approval[48] - The company plans to launch 28 new products in 2023, focusing on areas such as oncology, diabetes, and respiratory health[54] - The new product pipeline includes TQB3525, a liposomal formulation for anti-infection, and multiple oncology drugs like patritumab and aflibercept[54] - The sales revenue from new products accounted for approximately 38.1% of total revenue, up from about 20.7% in the previous year[70] - The new respiratory product Tianqing Suchang generated over RMB 500 million in revenue within six months of its launch[1] Market Presence and Strategy - The company has a significant presence in the pharmaceutical market, with a focus on both research and distribution across various therapeutic areas[43] - The company has a nationwide sales network with over 13,000 sales personnel, covering more than 90% of hospitals in China[43] - The company is actively pursuing mergers and acquisitions to enhance its product portfolio and market reach[54] - The anticipated revenue growth from new product launches is projected to contribute significantly to the overall financial performance in the upcoming fiscal year[54] - The company is entering a rapid development phase in internet healthcare, supported by national policies, which is transforming pharmaceutical marketing towards online models[61] Corporate Governance - The board of directors consists of nine executive directors, including the chairperson and CEO, and five independent non-executive directors[103] - The company has established various committees, including the Executive Committee, Audit Committee, Remuneration Committee, and Nomination Committee, to enhance board efficiency and encourage active participation[99] - The company has complied with all provisions of the Corporate Governance Code, except for specific attendance issues at the annual general meeting[98] - The board is responsible for overall corporate strategy and policy, focusing on the group's development and financial performance[99] - The company maintains high levels of corporate governance to ensure sustainable development, actively engaging with local and overseas investors[86] Shareholder Engagement and Dividends - A total of approximately HKD 1,006,318,000 (equivalent to approximately RMB 894,944,000) in dividends was distributed for the year 2020, with a proposed final dividend of HKD 0.02 per share[139] - The company maintains a policy of providing stable and sustainable dividends, dependent on financial performance, cash flow, and future capital needs[135] - The company has established a comprehensive policy for communication with shareholders, ensuring high standards of disclosure and financial transparency[133] - The board of directors attended the 2020 annual general meeting to respond to shareholder inquiries, with all resolutions passed by a poll vote[133] Operational Efficiency and Sustainability - The company is committed to enhancing its operational efficiency through strategic partnerships and collaborations in the pharmaceutical industry[54] - The company is focused on sustainability initiatives, aiming for a 30% reduction in carbon footprint by 2025[197] - The management team emphasized the importance of improving operational efficiency, aiming for a 5% reduction in costs over the next year[194] - The company is committed to environmental protection and has implemented measures to reduce energy consumption and waste during production[152] Awards and Recognition - The company has been recognized in the "Top 50 Best Companies in Asia-Pacific" by Forbes for three consecutive years from 2016 to 2018[33] - The company’s product, Kena (Bepotastine Besilate Tablets), won the "Outstanding Product Brand in Blood and Hematopoietic System" award in 2020, showcasing its innovation in the pharmaceutical sector[65] - The company has been included in the "Top 50 Global Pharmaceutical Companies" list by Pharm Exec for two consecutive years in 2019 and 2020[183] - The company has been recognized for its contributions to the development of the Chinese pharmaceutical industry, receiving multiple personal honors for its leadership[185] Employee and Management - The company has a total of 24,108 employees, including directors, as of December 31, 2020[173] - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including executives with backgrounds in finance and management from prestigious institutions[187][189][191] - The company has a strong emphasis on employee welfare and has been recognized as an outstanding employer in its region[187]

Financial Performance - The company reported revenue of approximately RMB 12,647.78 million for the six months ended June 30, 2020, representing a year-on-year growth of about 1.0%[11]. - Profit attributable to equity holders of the parent was approximately RMB 1,213.08 million, a decrease of about 16.0% compared to the same period last year[11]. - Basic earnings per share attributable to equity holders of the parent was approximately RMB 0.0964, down approximately 16.0% year-on-year[11]. - The company recorded revenue of approximately RMB 1,264,778 million, representing a year-on-year growth of about 1.0%[22]. - The group recorded a net profit attributable to the parent company of RMB 2,016,327 thousand, a decrease of 7.65% from RMB 2,183,801 thousand in the previous year[45]. - The company’s total comprehensive income for the period was RMB 2,067,157 thousand, compared to RMB 2,180,253 thousand in 2019, reflecting a decline of 5.19%[45]. - The group reported a revenue of RMB 12,647,775 thousand for the six months ended June 30, 2020, representing a slight increase of 0.96% compared to RMB 12,527,309 thousand in the same period of 2019[43]. - The group’s basic earnings per share for the period was RMB 0.096, compared to RMB 0.115 for the same period in 2019, indicating a decrease of about 16%[69]. Product and Market Development - Sales from new products accounted for approximately 34.8% of the total revenue[11]. - The sales of oncology drugs reached approximately RMB 401,756 million, accounting for about 31.8% of the company's total revenue[23]. - The sales of the new product Anxian (lenalidomide capsules) grew by approximately 69.3% to RMB 16,443 million[24]. - The sales of respiratory system drugs amounted to approximately RMB 59,732 million, representing about 4.7% of total revenue[27]. - The sales of liver disease drugs were approximately RMB 224,864 million, accounting for 17.8% of total revenue[23]. - The company has a diverse product portfolio covering various therapeutic areas, including liver disease, oncology, orthopedics, and respiratory diseases[13]. Research and Development - The company emphasizes R&D and innovation, with industry-leading investment in R&D and product innovation capabilities[13]. - Research and development expenses totaled approximately RMB 154,057,000, accounting for 12.2% of the group's revenue[33]. - The group had a total of 438 products in clinical trials or under production application, including 189 oncology drugs and 38 liver disease drugs[32]. - The company submitted 263 new patent applications during the review period, with 82 invention patents granted[22]. - The group reported research and development expenses of RMB 1,540,569,000 for the first half of 2020, down from RMB 1,625,550,000 in 2019, indicating a reduction of approximately 5%[64]. Financial Position and Cash Flow - As of June 30, 2020, cash and bank balances were approximately RMB 17,090.76 million[11]. - The group reported cash and bank balances of RMB 17,090,761,000 as of June 30, 2020, compared to RMB 11,911,210,000 at the end of 2019, showing an increase of about 43%[72]. - The total assets of the group were approximately RMB 6,834,834,000, up from RMB 5,829,925,000 at the end of 2019, representing a growth of 17.2%[37]. - The total liabilities increased to approximately RMB 2,684,549,000, resulting in a debt-to-asset ratio of 39.3%, compared to 30.9% at the end of 2019[37]. - The company reported a net cash flow from operating activities of RMB 1,555,549 thousand for the six months ended June 30, 2020, compared to RMB 3,507,412 thousand in the same period of 2019, indicating a decrease of approximately 55.6%[49]. - The total cash and cash equivalents at the end of the period reached RMB 15,666,602 thousand, up from RMB 6,328,584 thousand at the end of June 2019, representing an increase of approximately 148.5%[49]. Shareholder Information and Corporate Governance - The company has a stock option plan approved on May 28, 2013, allowing for the issuance of up to 494,146,147 shares, which is 10% of the issued share capital at the time[86]. - The board of directors consists of nine executive directors and four independent non-executive directors as of the report date[99]. - The company maintained high transparency during the COVID-19 pandemic by conducting a conference call that attracted over 490 analysts and fund managers to discuss the 2019 annual results and business developments[89]. - The company has complied with the Corporate Governance Code during the six months ending June 30, 2020, with a board comprising four independent non-executive directors, two of whom have financial management experience[93]. - The company repurchased 6,553,000 shares at a total cost of HKD 66,585,880 during the period ending June 30, 2020[97]. Market Recognition and Rankings - The company ranked 133rd in the list of China's top 500 listed companies, improving by 87 positions from the previous year[19]. - The company was recognized as one of the top 10 best listed biopharmaceutical companies in China for 2019[20]. - The company was included in the newly launched Hang Seng Shenzhen-Hong Kong Stock Connect Biotechnology 50 Index, ranking second among the top 10 constituent stocks[20]. - The company achieved a revenue of $3.373 billion, ranking 42nd in the global pharmaceutical companies list[20].